Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Global Forecast 2024-2030

Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Global Forecast 2024-2030

The Liver Fibrosis Drugs Market size was estimated at USD 14.28 billion in 2023 and expected to reach USD 15.57 billion in 2024, at a CAGR 9.74% to reach USD 27.38 billion by 2030.

Liver fibrosis drugs are pharmaceutical agents designed to prevent, halt, or reverse the process of liver fibrosis. Liver fibrosis itself is a pathological condition characterized by the excessive accumulation of extracellular matrix proteins, including collagen, which leads to the scarring of liver tissue. This condition can progress to more severe forms of liver disease, such as cirrhosis and liver cancer if left untreated. These drugs aim to disrupt the fibrogenic processes, mitigate inflammation, and improve liver function. The rising incidence of conditions such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease fuels the need for effective treatments, including liver fibrosis drugs. Rising investments by pharmaceutical companies and research institutions for developing novel therapeutics are expanding the development of liver fibrosis drugs. The high development and production costs of liver fibrosis drugs hamper the growth of the market. The availability of international healthcare programs aimed at combating liver diseases and promoting liver health with increasing awareness and funding for liver fibrosis research and drug development are expected to create opportunities for market growth.

Regional Insights

The Americas, particularly North America, stands as a pivotal region in the development and adoption of liver fibrosis drugs. The Americas represents a significant region in pharmaceutical innovation, regulatory frameworks, and health spending, making it a primary market for liver fibrosis therapies. The high prevalence of liver diseases due to factors such as obesity and alcohol consumption further drives the need for effective treatments in this region. Additionally, strong support for liver disease research from both government and private sectors bolsters the development of new and advanced treatments for liver fibrosis. The Asia-Pacific region is witnessing rapid growth in the liver fibrosis drug market, attributed to increasing healthcare expenditure, growing awareness of liver diseases, and improving healthcare infrastructure. Countries such as Japan, China, and South Korea are at the forefront, with Japan being a significant contributor due to its advanced healthcare system and high rate of pharmaceutical R&D. The prevalence of hepatitis B and C, major risk factors for liver fibrosis, is relatively high in this region, driving the urgency for effective treatment options. Moreover, the expanding middle-class population is increasingly able to afford advanced therapies, thereby boosting the market for liver fibrosis drugs in APAC. The EMEA region presents a diverse outlook on the market for liver fibrosis drugs. Europe is characterized by its strong regulatory frameworks, widespread healthcare access, and high awareness of liver conditions, making it a major market for these therapies. Initiatives by the European Association for the Study of the Liver (EASL) further support research and awareness, enhancing the landscape for liver fibrosis treatment. Certain countries in the Middle East are witnessing growth in healthcare infrastructure, which could lead to increased access to liver fibrosis drugs. Africa’s market growth is hindered by economic constraints, but international health organizations are stepping in to improve the situation through educational and treatment programs.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Liver Fibrosis Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing prevalence of chronic liver diseases worldwide
Favorable reimbursement policies for treatment of liver fibrosis

Market Restraints

Complexity in formulation and development of liver fibrosis drugs

Market Opportunities

Emerging research funding for the development of novel liver fibrosis drugs
Improvements in liver imaging techniques and biomarkers for liver fibrosis

Market Challenges

Stringent regulatory frameworks for drug approval of liver fibrosis

Market Segmentation Analysis

Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Liver Fibrosis Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Liver Fibrosis Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis

Boehringer Ingelheim has unveiled results from a Phase II clinical trial involving survodutide (BI 456906), a prospective treatment for metabolic dysfunction-associated steatohepatitis (MASH). The trial showcased that a remarkable 83.0% of adult participants receiving survodutide experienced a significant amelioration in their condition compared to a mere 18.2% in the placebo group, marking a response difference of 64.8% (with a confidence interval of 51.1% to 78.6%, and a p-value of less than 0.0001). This significant improvement was observed without any worsening in fibrosis stages F1, F2, and F3, indicating effectiveness in not just halting but potentially reversing the disease's progression. Achieving both its primary and all secondary endpoints, including notable enhancements in liver fibrosis, survodutide is now poised to redefine the treatment landscape for MASH, a disease intricately linked with a wide range of cardiovascular, renal, and metabolic disorders.

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease

Ipsen alongside GENFIT have announced the significant advancement of their new drug, elafibranor, in the regulatory process. The U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for elafibranor, signifying a potential breakthrough in the treatment of the rare cholestatic liver disease, Primary Biliary Cholangitis (PBC). This investigational drug, a once-daily oral dual peroxisome proliferator-activated receptor alpha/delta (PPAR α,δ) agonist, stands on the cusp of becoming the inaugural second-line therapy for PBC in nearly ten years.

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its New Drug Application (NDA) for resmetirom. This significant milestone targets the management of NASH with associated liver fibrosis in adult patients. Additionally, the FDA has indicated it does not foresee the necessity for an advisory committee meeting to evaluate the application, underscoring the thoroughness of the submitted documentation and the potential impact of resmetirom on treating this chronic liver condition.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Liver Fibrosis Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
Antifibrotic Agents
Antioxidant Inflammation Modulators
Antiviral Drugs
Immune Modulators
Distribution Channel
Offline Pharmacies
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year